Eiki Ichihara

List of Publications by Year
in descending order

87 papers	2,060 citations	279798 23 h-index	254184 43 g-index
90 all docs	90 docs citations	90 times ranked	3172 citing authors

#	Article	IF	Citations
1	Pulmonary Aspergilloma and Allergic Bronchopulmonary Aspergillosis Following the 2018 Heavy Rain Event in Western Japan. Internal Medicine, 2022, 61, 379-383.	0.7	1
2	Osimertinib in poor performance status patients with T790M-positive advanced non-small-cell lung cancer after progression of first- and second-generation EGFR-TKI treatments (NEJ032B). International Journal of Clinical Oncology, 2022, 27, 112-120.	2.2	9
3	Identification of targetable kinases in idiopathic pulmonary fibrosis. Respiratory Research, 2022, 23, 20.	3.6	8
4	Nintedanib plus chemotherapy for nonsmall cell lung cancer with idiopathic pulmonary fibrosis: a randomised phase 3 trial. European Respiratory Journal, 2022, 60, 2200380.	6.7	34
5	Pembrolizumab in advanced NSCLC patients with poor performance status and high PD-L1 expression: OLCSG 1801. International Journal of Clinical Oncology, 2022, 27, 1139-1144.	2.2	7
6	Three doses of mRNA COVIDâ€19 vaccine protects from SARSâ€CoVâ€2 infections in Japan. Journal of Internal Medicine, 2022, 292, 687-689.	6.0	2
7	Preventive effect of goshajinkigan against peripheral neuropathy induced by paclitaxel-containing chemotherapy: An open-label, randomized, phase II study.. Journal of Clinical Oncology, 2022, 40, TPS12141-TPS12141.	1.6	0
8	CD8+ T-cell Responses Are Boosted by Dual PD-1/VEGFR2 Blockade after EGFR Inhibition in Egfr-Mutant Lung Cancer. Cancer Immunology Research, 2022, 10, 1111-1126.	3.4	10
9	Mixed Response to Cancer Immunotherapy is Driven by Intratumor Heterogeneity and Differential Interlesion Immune Infiltration. Cancer Research Communications, 2022, 2, 739-753.	1.7	2
10	Characteristics of patients with EGFR-mutant non-small-cell lung cancer who benefited from immune checkpoint inhibitors. Cancer Immunology, Immunotherapy, 2021, 70, 101-106.	4.2	26
11	Impact of previous thoracsic radiation therapy on the efficacy of immune checkpoint inhibitors in advanced non-smasll-cell lung cancer. Japanese Journal of Clinical Oncology, 2021, 51, 279-286.	1.3	7
12	Randomized study comparing mannitol with furosemide for the prevention of cisplatinâ€induced renal toxicity in nonâ€small cell lung cancer: The OLCSG1406 trial. Asia-Pacific Journal of Clinical Oncology, 2021, 17, 101-108.	1.1	7
13	Comparison of bronchoscopy and computed tomography-guided needle biopsy for re-biopsy in non-small cell lung cancer patients. Respiratory Investigation, 2021, 59, 240-246.	1.8	3
14	Significance of PD-L1 expression in the cytological samples of non-small cell lung cancer patients treated with immune checkpoint inhibitors. Journal of Cancer Research and Clinical Oncology, 2021, 147, 3749-3755.	2.5	6
15	VEGFR2 blockade augments the effects of tyrosine kinase inhibitors by inhibiting angiogenesis and oncogenic signaling in oncogeneâ€driven nonâ€smallâ€cell lung cancers. Cancer Science, 2021, 112, 1853-1864.	3.9	29
16	A Case of Lung Cancer That Showed an Abscopal Effect After Irradiation of Simultaneous Oropharyngeal Cancer. Japanese Journal of Lung Cancer, 2021, 61, 109-112.	0.1	0
17	A novel osimertinib-resistant human lung adenocarcinoma cell line harbouring mutant EGFR and activated IGF1R. Japanese Journal of Clinical Oncology, 2021, 51, 956-965.	1.3	6
18	Impact on second-line treatment after failure of immune checkpoint inhibitor (ICI) combination chemotherapy in extensive-disease small cell lung cancer: Experience of the Okayama Lung Cancer Study Group.. Journal of Clinical Oncology, 2021, 39, e20590-e20590.	1.6	0

#	Article	IF	Citations
19	The effects of antibiotics on the efficacy of immune checkpoint inhibitors in patients with nonâ€“small-cell lung cancer differ based on PD-L1 expression. European Journal of Cancer, 2021, 149, 73-81.	2.8	34
20	Pembrolizumab plus pemetrexedâ€platinum for metastatic nonsquamous nonâ€“smallâ€cell lung cancer: KEYNOTEâ€189 Japan Study. Cancer Science, 2021, 112, 3255-3265.	3.9	26
21	SHP2 Inhibition Enhances the Effects of Tyrosine Kinase Inhibitors in Preclinical Models of Treatment-naÃ¯ve ALK-, ROS1-, or EGFR-altered Nonâ€“small Cell Lung Cancer. Molecular Cancer Therapeutics, 2021, 20, 1653-1662.	4.1	7
22	Triple therapy with osimertinib, bevacizumab and cetuximab in EGFRâ€‘mutant lung cancer with HIFâ€‘1Î±/TGFâ€Î± expression. Oncology Letters, 2021, 22, 639.	1.8	1
23	Response to letter re: The effects of antibiotics on the efficacy of immune-checkpoint inhibitors in non-small cell lung cancer patients differ according to PD-L1 expression. European Journal of Cancer, 2021, 157, 523-524.	2.8	0
24	A phase I/II study of osimertinib in EGFR exon 20 insertion mutation-positive non-small cell lung cancer. Lung Cancer, 2021, 162, 140-146.	2.0	32
25	An Update on Targeted Therapy in Advanced Non-small Cell Lung Cancer. Japanese Journal of Lung Cancer, 2021, 61, 377-382.	0.1	0
26	Managing Lung Cancer with Comorbid Interstitial Pneumonia. Internal Medicine, 2020, 59, 163-167.	0.7	14
27	Patientsâ€™ preferences and perceptions of lung cancer treatment decision making: results from Okayama lung cancer study group trial 1406. Acta OncolÃ³gica, 2020, 59, 324-328.	1.8	2
28	The impact of body mass index on the efficacy of anti-PD-1/PD-L1 antibodies in patients with non-small cell lung cancer. Lung Cancer, 2020, 139, 140-145.	2.0	68
29	Influence of age on the efficacy of immune checkpoint inhibitors in advanced cancers: a systematic review and meta-analysis. Acta OncolÃ³gica, 2020, 59, 249-256.	1.8	28
30	Beneficial effect of erlotinib and trastuzumab emtansine combination in lung tumors harboring EGFR mutations. Biochemical and Biophysical Research Communications, 2020, 532, 341-346.	2.1	10
31	Utility of immune checkpoint inhibitors in nonâ€smallâ€cell lung cancer patients with poor performance status. Cancer Science, 2020, 111, 3739-3746.	3.9	20
32	Immune checkpoint inhibitor efficacy and safety in older non-small cell lung cancer patients. Japanese Journal of Clinical Oncology, 2020, 50, 1447-1453.	1.3	14
33	Treatment Rationale and Design of a Phase III Study of Afatinib or Chemotherapy in Patients with Nonâ€“small-cell Lung Cancer Harboring Sensitizing Uncommon Epidermal Growth Factor Receptor Mutations (ACHILLES/TORG1834). Clinical Lung Cancer, 2020, 21, e592-e596.	2.6	5
34	Rapid Disease Progression of Advanced Non-small Cell Lung Cancer Five Months after Cessation of Pembrolizumab. Acta Medica Okayama, 2020, 74, 423-425.	0.2	2
35	Association between Histological Types and Enhancement of Dynamic CT for Primary Lung Cancer. Acta Medica Okayama, 2020, 74, 129-135.	0.2	1
36	Summary of the Japanese Respiratory Society statement for the treatment of lung cancer with comorbid interstitial pneumonia. Respiratory Investigation, 2019, 57, 512-533.	1.8	36

#	Article	IF	Citations
37	Granulation Tissue-induced Pseudo-relapse During Nivolumab Treatment in Advanced Non-small Cell Lung Cancer. In Vivo, 2019, 33, 2113-2115.	1.3	4
38	Rapid Acquisition of Alectinib Resistance in ALK-Positive Lung Cancer With High Tumor Mutation Burden. Journal of Thoracic Oncology, 2019, 14, 2009-2018.	1.1	22
39	Primary Resistance to Alectinib Was Lost after Bevacizumab Combined Chemotherapy in ALK-Rearranged Lung Adenocarcinoma. Journal of Thoracic Oncology, 2019, 14, e168-e169.	1.1	9
40	Efficacy of afatinib treatment for lung adenocarcinoma harboring exon 18 delE709_T710insD mutation. Japanese Journal of Clinical Oncology, 2019, 49, 786-788.	1.3	13
41	Programmed cell death-ligand 1 expression and efficacy of cisplatin-based chemotherapy in lung cancer: A sub-analysis of data from the two Okayama Lung Cancer Study Group prospective feasibility studies. Respiratory Investigation, 2019, 57, 460-465.	1.8	2
42	The effect and safety of immune checkpoint inhibitor rechallenge in non-small cell lung cancer. Japanese Journal of Clinical Oncology, 2019, 49, 762-765.	1.3	43
43	Chemoradiotherapy for locally advanced lung cancer patients with interstitial lung abnormalities. Japanese Journal of Clinical Oncology, 2019, 49, 458-464.	1.3	17
44	Re-administration of osimertinib in osimertinib-acquired resistant non-small-cell lung cancer. Lung Cancer, 2019, 132, 54-58.	2.0	15
45	Significance of re-biopsy of histological tumor samples in advanced non-small-cell lung cancer in clinical practice. International Journal of Clinical Oncology, 2019, 24, 41-45.	2.2	5
46	Randomized phase II study comparing mannitol with furosemide for the prevention of cisplatin-induced renal toxicity in advanced non-small cell lung cancer: The OLCSG1406 trial.. Journal of Clinical Oncology, 2019, 37, e23105-e23105.	1.6	1
47	MET or NRAS amplification is an acquired resistance mechanism to the third-generation EGFR inhibitor naquotinib. Scientific Reports, 2018, 8, 1955.	3.3	34
48	A Phase II Study of Trastuzumab Emtansine in HER2-Positive Nonâ€“Small Cell Lung Cancer. Journal of Thoracic Oncology, 2018, 13, 273-279.	1.1	119
49	Treatment Rationale and Design for J-SONIC: AÂRandomized Study of Carboplatin Plus Nab-paclitaxel With or Without Nintedanib for Advanced Nonâ€“Small-cell Lung Cancer With Idiopathic Pulmonary Fibrosis. Clinical Lung Cancer, 2018, 19, e5-e9.	2.6	44
50	Potential influence of interleukin-6 on the therapeutic effect of gefitinib in patients with advanced non-small cell lung cancer harbouring EGFR mutations. Biochemical and Biophysical Research Communications, 2018, 495, 360-367.	2.1	15
51	A phase II trial of EGFR-TKI readministration with afatinib in advanced non-small-cell lung cancer harboring a sensitive non-T790M EGFR mutation: Okayama Lung Cancer Study Group trial 1403. Cancer Chemotherapy and Pharmacology, 2018, 82, 1031-1038.	2.3	18
52	Combined effect of cabozantinib and gefitinib in crizotinibâ€resistant lung tumors harboring <scp>ROS</scp>1 fusions. Cancer Science, 2018, 109, 3149-3158.	3.9	20
53	The effect and safety of an immune checkpoint inhibitor rechallenge in non-small cell lung cancer.. Journal of Clinical Oncology, 2018, 36, e21147-e21147.	1.6	2
54	Clinical significance of repeat rebiopsy in detecting the EGFR T790M secondary mutation in patients with non-small cell lung cancer. Oncotarget, 2018, 9, 29525-29531.	1.8	28

#	Article	IF	Citations
55	Immune checkpoint inhibitor efficacy and safety in elderly non-small cell lung cancer patients.. Journal of Clinical Oncology, 2018, 36, e21034-e21034.	1.6	0
56	SFK/FAK Signaling Attenuates Osimertinib Efficacy in Both Drug-Sensitive and Drug-Resistant Models of EGFR-Mutant Lung Cancer. Cancer Research, 2017, 77, 2990-3000.	0.9	106
57	Discomfort during bronchoscopy performed after endobronchial intubation with fentanyl and midazolam: a prospective study. Japanese Journal of Clinical Oncology, 2017, 47, 434-437.	1.3	6
58	Three-Arm Randomized Trial of Sodium Alginate for Preventing Radiation-Induced Esophagitis in Locally Advanced Nonâ€“Small Cell Lung Cancer Receiving Concurrent Chemoradiotherapy: The OLCSG1401 Study Protocol. Clinical Lung Cancer, 2017, 18, 245-249.	2.6	8
59	A phase II trial of carboplatin plus S-1 for elderly patients with advanced non-small-cell lung cancer with wild-type epidermal growth factor receptor: The Okayama Lung Cancer Study Group Trial 1202. Lung Cancer, 2017, 112, 188-194.	2.0	5
60	Phase II Study of the EGFR-TKI Rechallenge With Afatinib in Patients With Advanced NSCLC Harboring Sensitive EGFR Mutation Without T790M: Okayama Lung Cancer Study Group Trial OLCSG 1403. Clinical Lung Cancer, 2017, 18, 241-244.	2.6	9
61	The effect of nivolumab treatment for central nervous system metastases in non-small cell lung cancer.. Journal of Clinical Oncology, 2017, 35, e20601-e20601.	1.6	17
62	Protective Effects of Bisoprolol against Acute Exacerbation in Moderate-to-Severe Chronic Obstructive Pulmonary Disease. Acta Medica Okayama, 2017, 71, 453-457.	0.2	4
63	Chemoradiotherapy (CRT) for locally-advanced (LA) lung cancer patients with interstitial lung abnormalities (ILA).. Journal of Clinical Oncology, 2017, 35, e20057-e20057.	1.6	0
64	Potential influence of being overweight on the development of hepatic dysfunction in Japanese patients with EGFR-mutated non-small cell lung cancer undergoing gefitinib monotherapy: the Okayama Lung Cancer Study Group experience. Cancer Chemotherapy and Pharmacology, 2016, 78, 941-947.	2.3	6
65	Protocol Design for the Bench to Bed Trial in Alectinib-Refractory Nonâ€“Small-Cell Lung Cancer Patients Harboring the EML4-ALK Fusion Gene (ALRIGHT/OLCSG1405). Clinical Lung Cancer, 2016, 17, 602-605.	2.6	10
66	Nonâ€“Small Cell Lung Cancer Cells Acquire Resistance to the ALK Inhibitor Alectinib by Activating Alternative Receptor Tyrosine Kinases. Cancer Research, 2016, 76, 1506-1516.	0.9	115
67	Short-term low-volume hydration in cisplatin-based chemotherapy for patients with lung cancer: the second prospective feasibility study in the Okayama Lung Cancer Study Group Trial 1201. International Journal of Clinical Oncology, 2016, 21, 81-87.	2.2	26
68	Second primary cancer in survivors of locally advanced NSCLC treated with concurrent chemoradiation followed by surgery.. Journal of Clinical Oncology, 2016, 34, 10100-10100.	1.6	0
69	Association with consolidation chemotherapy after concurrent chemoradiotherapyfollowed by surgery and the disease free survival in patients with stage III non-small cell lung cancer (NSCLC).. Journal of Clinical Oncology, 2016, 34, e20053-e20053.	1.6	0
70	Challenges in Bevacizumab and Gefitinib Combination Therapy for Patients with Nonâ€“Small-Cell Lung Cancer. Journal of Thoracic Oncology, 2015, 10, e79.	1.1	0
71	Impact of body surface area on survival in EGFR-mutant non-small cell lung cancer patients treated with gefitinib monotherapy: observational study of the Okayama Lung Cancer Study Group 0703. Cancer Chemotherapy and Pharmacology, 2015, 76, 251-256.	2.3	11
72	Phase II Trial of Gefitinib in Combination with Bevacizumab as First-Line Therapy for Advanced Nonâ€“Small Cell Lung Cancer with Activating EGFR Gene Mutations: The Okayama Lung Cancer Study Group Trial 1001. Journal of Thoracic Oncology, 2015, 10, 486-491.	1.1	93

#	Article	IF	Citations
73	RAS-MAPK dependence underlies a rational polytherapy strategy in EML4-ALKâ€“positive lung cancer. Nature Medicine, 2015, 21, 1038-1047.	30.7	245
74	Crizotinib to overcome alectinib-resistance in non-small cell lung cancer (NSCLC) harboring EML4-ALK.. Journal of Clinical Oncology, 2015, 33, e19140-e19140.	1.6	1
75	A New Human Lung Adenocarcinoma Cell Line Harboring the EML4-ALK Fusion Gene. Japanese Journal of Clinical Oncology, 2014, 44, 963-968.	1.3	11
76	Factors affecting PS deterioration at the time of relapse after the first-line EGFR-TKI therapy in EGFR-mutant advanced NSCLC.. Journal of Clinical Oncology, 2014, 32, e19102-e19102.	1.6	0
77	Impact of physical size on gefitinib efficacy in patients with non-small cell lung cancer harboring EGFR mutations. Lung Cancer, 2013, 81, 435-439.	2.0	28
78	Acquired Resistance to EGFR Inhibitors Is Associated with a Manifestation of Stem Cellâ€“like Properties in Cancer Cells. Cancer Research, 2013, 73, 3051-3061.	0.9	241
79	Lower gefitinib dose led to earlier resistance acquisition before emergence of T790M mutation in epidermal growth factor receptorâ€mutated lung cancer model. Cancer Science, 2013, 104, 1440-1446.	3.9	34
80	Afatinib Prolongs Survival Compared with Gefitinib in an Epidermal Growth Factor Receptor-Driven Lung Cancer Model. Molecular Cancer Therapeutics, 2013, 12, 589-597.	4.1	62
81	Impact of body surface area (BSA) on efficacy of gefitinib in patients with non-small cell lung cancer (NSCLC).. Journal of Clinical Oncology, 2013, 31, e19167-e19167.	1.6	0
82	Impact of body surface area on efficacy of gefitinib in patients with non-small cell lung cancer harboring activating epidermal growth factor receptor mutation.. Journal of Clinical Oncology, 2012, 30, 2607-2607.	1.6	1
83	Survival post-progression (SPP) in phase III trials of chemotherapy in advanced NSCLC: Its potentially different impact on OS in the first-line and salvage settings.. Journal of Clinical Oncology, 2012, 30, e18027-e18027.	1.6	0
84	Difference in incidence and pattern of salvage treatment after failure to first-line epidermal growth factor receptor-tyrosine kinase inhibitor (EGFR-TKI) monotherapy and standard cytotoxic chemotherapy in pts with advanced non-small cell lung cancer (NSCLC) harboring EGFR mutations: Okayama Lung Cancer Study Group experience.. Journal of Clinical Oncology, 2012, 30, 7576-7576.	1.6	0
85	Role of Survival Post-Progression in Phase III Trials of Systemic Chemotherapy in Advanced Non-Small-Cell Lung Cancer: A Systemic Review. PLoS ONE, 2011, 6, e26646.	2.5	66
86	Targeting angiogenesis in cancer therapy. Acta Medica Okayama, 2011, 65, 353-62.	0.2	22
87	Effects of Vandetanib on Lung Adenocarcinoma Cells Harboring Epidermal Growth Factor Receptor T790M Mutation In vivo. Cancer Research, 2009, 69, 5091-5098.	0.9	65